Literature DB >> 35925055

[Principles of the perioperative management of direct oral anticoagulants].

Maik von der Forst1, Benedict Morath2, Martina Schwald2, Markus A Weigand1, Felix C F Schmitt3.   

Abstract

Within the approved indications direct oral anticoagulants (DOAC) are increasingly gaining acceptance instead of vitamin K antagonists (VKA). In the last 12 months 5 guidelines relevant to the perioperative management of DOACs have been updated. This article summarizes the current recommendations for the perioperative management of treatment with DOACs. The available substances and their pharmacological properties as well as the possibilities for specific laboratory diagnostics of the effect of DOAC are explained. Special focus is placed on anesthesiologically important aspects of substance-specific preoperative and postoperative intermission intervals, the procedure for neuraxial regional anesthesia and antagonization with specific antidotes in cases of life-threatening bleeding.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Anesthesia, regional; Antidotes; Bleeding risk; Blood coagulation; Bridging

Mesh:

Substances:

Year:  2022        PMID: 35925055     DOI: 10.1007/s00101-022-01142-7

Source DB:  PubMed          Journal:  Anaesthesiologie        ISSN: 2731-6858


  8 in total

1.  A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury.

Authors:  D Oberladstätter; W Voelckel; C Schlimp; J Zipperle; B Ziegler; O Grottke; H Schöchl
Journal:  Anaesthesia       Date:  2020-09-18       Impact factor: 6.955

2.  Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.

Authors:  Mohinder S Bathala; Hiroshi Masumoto; Toshihiro Oguma; Ling He; Chris Lowrie; Jeanne Mendell
Journal:  Drug Metab Dispos       Date:  2012-08-30       Impact factor: 3.922

3.  The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Jacques Duranteau; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Marc Maegele; Giuseppe Nardi; Louis Riddez; Charles-Marc Samama; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2019-03-27       Impact factor: 9.097

4.  Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).

Authors:  Matthew W Sherwood; James D Douketis; Manesh R Patel; Jonathan P Piccini; Anne S Hellkamp; Yuliya Lokhnygina; Alex C Spyropoulos; Graeme J Hankey; Daniel E Singer; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Richard C Becker
Journal:  Circulation       Date:  2014-02-19       Impact factor: 29.690

5.  The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.

Authors:  Stefan Blech; Thomas Ebner; Eva Ludwig-Schwellinger; Joachim Stangier; Willy Roth
Journal:  Drug Metab Dispos       Date:  2007-11-15       Impact factor: 3.922

6.  Apixaban metabolism and pharmacokinetics after oral administration to humans.

Authors:  Nirmala Raghavan; Charles E Frost; Zhigang Yu; Kan He; Haiying Zhang; W Griffith Humphreys; Donald Pinto; Shiangyuan Chen; Samuel Bonacorsi; Pancras C Wong; Donglu Zhang
Journal:  Drug Metab Dispos       Date:  2008-10-02       Impact factor: 3.922

7.  Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.

Authors:  Andrew M Demchuk; Patrick Yue; Elena Zotova; Juliet Nakamya; Lizhen Xu; Truman J Milling; Tomoyuki Ohara; Joshua N Goldstein; Saskia Middeldorp; Peter Verhamme; Jose Luis Lopez-Sendon; Pamela B Conley; John T Curnutte; John W Eikelboom; Mark Crowther; Stuart J Connolly
Journal:  Stroke       Date:  2021-05-10       Impact factor: 10.170

8.  Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.

Authors:  Alexander P Benz; Lizhen Xu; John W Eikelboom; Saskia Middeldorp; Truman J Milling; Mark Crowther; Patrick Yue; Pamela Conley; Genmin Lu; Stuart J Connolly
Journal:  Thromb Haemost       Date:  2022-01-07       Impact factor: 6.681

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.